Midas Pharma GmbH

Privately held: no public share price · Germany

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Preclinical / Unstaged
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.